Search results

Filters
Close
ADDED DATE
Added date
TOPICS Please select
WATCH / LISTEN / READ TIME
HFSA 25: The ATTRibute-CM Trial
Author(s): Ahmad Masri Added: 6 months ago
HFSA 2025 - Post hoc analysis of ATTRibute-CM reveals significant reduction in cardiovascular mortality and death after 30 months of acoramidis in patients with ATTR-CM.Dr Ahmad Masri (Oregon Health & Science University, US) joins us to discuss a post hoc exploratory analysis from the ATTRibute-CM trial examining the timing and magnitude of cardiovascular outcome reductions with acoramidis in… View more

Heart Failure
Diagnostic Red Flags are Common in Hypertrophic Cardiomyopathy, Study Finds
Added: 7 months ago Source:  Radcliffe Cardiology
According to European Society of Cardiology (ESC) guidelines, a systematic search for diagnostic clues, or ‘red flags’ (RFs), is recommended in patients with hypertrophic cardiomyopathy (HCM) to help tailor disease management. A new study published in the European Heart Journal has investigated the prevalence and clinical significance of these RFs across different HCM phenotypes and clinical… View more

Imaging & Diagnostics

Inherited and Congenital Cardiac Conditions
AI Screening Improves ATTR-CM Diagnosis Rates
Added: 5 months ago Source:  Radcliffe Cardiology
An artificial intelligence (AI)-augmented clinical programme may significantly improve the detection of transthyretin amyloid cardiomyopathy (ATTR-CM), a condition that is frequently underdiagnosed, according to the results of a new nonrandomized clinical trial.¹ The study evaluated an AI model, ATTRACTnet, in a real-world setting to identify patients missed by usual care.The ATTRACTnet model was… View more

Imaging & Diagnostics

Digital Health
Targeting Obesity for Heart Failure
Author(s): Emily Morris , Oliver J Rider Added: 3 months ago

Cardiovascular Renal Metabolic

Heart Failure
AHA 24: Nexiguran Ziclumeran for ATTR-CM
Author(s): Marianna Fontana Added: 1 year ago
AHA Conference 2024 - Safety and efficacy outcomes of nexiguran ziclumeran (NTLA-2001) in patients with transthyretin amyloidosis with cardiomyopathy (ATTR-CM).Dr Marianna Fontana (University College London, London, UK) joins us onsite at AHA Conference to discuss the findings from the nexiguran ziclumeran for ATTR-CM trial (NCT04601051).Dr Fontana discusses a phase 1, ongoing, open-label, single… View more

Heart Failure
Medhi Eskandari
Job title: Consultant Cardiologist
Dr Mehdi Eskandari is an Australian-trained Consultant Cardiologist providing comprehensive adult cardiology care. At Qualitas in Melbourne, he sees patients with common cardiac presentations, including chest pain, breathlessness, palpitations, hypertension, arrhythmias and cardiovascular risk management, with a focus on accurate diagnosis and evidence-based, practical treatment plans.After… View more
Important Gaps in Heart Failure Care
Author(s): Zara Latif , Tracy Makuvire , Sarah Schroeder , et al Added: 4 months ago

Heart Failure
Analysis of Emerging Data for the Treatment of Amyloidosis
Author(s): Julian Gillmore , Margot K Davis Added: 7 months ago
This programme, featuring Prof Julian Gillmore (University College London, London, UK) and Dr Margot Davis (Vancouver General Hospital, Vancouver, CA) offers an in-depth exploration of ATTR amyloidosis, highlighting the value of observational research in understanding disease presentation, treatment patterns, and outcomes. Viewers will learn about the pathophysiology and spectrum of the condition… View more

Heart Failure
Author(s): Julian Gillmore , Margot K Davis , Ahmad Masri , et al Added: 1 year ago
First presented at ESC 2024, this on-demand programme sees Prof Julian Gillmore (University College London, London, UK) lead a distinguished faculty compromising of Dr Ahmad Masri (Oregon Health & Science University Medical Group, Portland, US), Dr Margot Davis (University of British Columbia, Vancouver, CA), and Dr Giuseppe Vergaro (Sant’Anna, Pisa, IT).The faculty present recent epidemiological… View more

Heart Failure
ICOS-CORE Whitepaper Calls for Rigorous Evidence to Support Cardio-oncology Rehabilitation
Added: 8 months ago Source:  Radcliffe Cardiology
A new whitepaper from the International Cardio-Oncology Society (ICOS) CORE working group outlines a critical roadmap for advancing the cardiovascular care of cancer survivors. Published in the European Heart Journal, the paper reviews the current evidence for cardio-oncology rehabilitation and exercise (CORE) programmes and sets new standards for future research to address significant knowledge… View more

Prevention & Chronic Conditions

CV Disease in Special Populations